顺铂联合斯奇康胸腔内注入治疗恶性胸腔积液28例

目的:探讨胸腔内注入顺铂和斯奇康治疗恶性胸腔积液的疗效.方法:经病理细胞学证实为肺癌胸膜转移的恶性胸腔积液56例,经胸腔插管引流术排尽胸液后,随机分成两组,治疗组(28例)胸腔内注入顺铂40 mg/m2和斯奇康6 mg,对照组(28例)仅用顺铂,不用斯奇康,1周后重复1次,最多3次.观察疗效、生存期以及毒副反应.结果:总有效率治疗组为82.1%,对照组为53.6%,两组比较有显著性差异(P＜0.05);治疗组0.5,1,1.5年生存率为85.7%,57.1%,35.7%,分别高于对照组的60.7%,35.7%,10.7%.治疗组发热较对照组有显著性差异(P＜0.05).结论:顺铂加斯奇康胸腔内注射治疗恶性胸腔积液,是一种有效、低毒、可耐受的方法.

Clinical Observation of Malignant Pleural Effusion Using Cisplatine and Siqikang Intrapleurally Injection

Objective:To evaluate the efficacy of Cisplati ne and Siqikang(BCG polysaccharide and nucleic acid)by injection through thoracic tube intubation on treatme nt malignant pleural effusion.Methods:56cases with malignant pleural effu sion,after drainage,Cisplatine40mg /m 2 and Siqikang 6mg were injected into p leural cavity in therapy group,and Cisplatine 40mg /m 2 only in control group.The treatment was repeated after a week,no more than three times efficacy,survival rate and toxicities were ev aluated.Results:The response rate was 82.1%in therapy group and 53.6%i n control group.There was sighificant difference in two groups(P<0.05).The half -year,one -year,one and half -year survival rates were 85.7%,57.1%,35.7%in therapy group and 60.7%,35.7%,10.7%in control group,respectively.Conclusion:The treatment of Cisplatine combined Siqikang through thoracic tube is r egarded as effective,less toxicities and well tolerated method for malignant pleu ral effusion.